TY - JOUR T1 - ABPA syndrome (ABPAs) in CF: FEV1 decline, infectious exacerbations and BMI before and after the year of diagnosis (index year), a case control study JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P1966 AU - Frans De Baets AU - Simeon Wanyana AU - Linde De Keyzer AU - Petra Schelstraete AU - Filomeen Haerynck AU - Muriel Thomas AU - Sabine Van daele Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P1966.abstract N2 - ABPAs is a complication occurring in 10 to 15% of the CF patients. In case of late diagnosis bronchial damage can be considerably. A high degree of suspicion is mandatory and indicators of ABPAs must be followed carefully. We intend to study facilitators and consequences of ABPAs.Methods:We performed a case control study relying on data from the Belgian CF register. One hundred and fifty five ABPAs patients matched for age, gender and P. aeruginosa colonisation were compared to 356 controls. FEV1 decline, infectious exacerbations and BMI were studied over a period of 10 years before and 10 years after the index year.Results :Before the index year mean cumulative FEV1values are significantly lower in the ABPAs group (p<0.002), although the decline over the years is comparable. After the index year mean cumulative FEV1 values remain significantly different between both groups (p<0.0001) but there is a significantly steeper decline in FEV1over the 10 years period in the ABPAs group.Before the index year ABPAs patients spent significantly more days in hospital for IV antibiotic treatment (p<0.001). This difference persists after the index year (p<0.0001).BMI is significantly lower in the ABPAs patient group, both before and after the index year (p<0.001).Conclusions:Lower FEV1, lower BMI and increased need for IV antibiotics seems to facilitate the development of ABPAs. ABPAs favours accelerated bronchial damage leading to a further increased need for IV antibiotics and a steeper decline in FEV1. ER -